Patrick Lamy Sells 925 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 925 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $28,480.75. Following the completion of the sale, the vice president now owns 17,858 shares in the company, valued at $549,847.82. This trade represents a 4.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Akero Therapeutics Trading Down 0.5 %

NASDAQ AKRO opened at $28.89 on Friday. The stock has a market capitalization of $2.02 billion, a P/E ratio of -7.70 and a beta of -0.23. The business has a 50 day simple moving average of $30.81 and a 200 day simple moving average of $27.08. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Research analysts expect that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

A number of large investors have recently bought and sold shares of AKRO. Wellington Management Group LLP boosted its position in shares of Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares in the last quarter. Janus Henderson Group PLC raised its stake in Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after buying an additional 201,225 shares during the period. RTW Investments LP boosted its holdings in Akero Therapeutics by 9.0% in the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after acquiring an additional 487,450 shares in the last quarter. Perceptive Advisors LLC grew its stake in Akero Therapeutics by 8.1% in the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after acquiring an additional 112,426 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in Akero Therapeutics in the third quarter valued at approximately $37,392,000.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AKRO. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup began coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $65.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.83.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.